Clinical Trial Update: A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 mass balance study of [14C] SHR6508 in Chinese hemodialysis patients with secondary hyperparathyroidism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperparathyroidism

Drugs mentioned

• SHR6508 (SHR6508)

Snippet

Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. | Conditions: Secondary Hyperparathyroidism | Phase 1 | Status: COMPLETED